Concomitant 177 Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

ConclusionsOur data confirm that177Lu-DOTATATE-capecitabine therapy is effective in achieving an objective response in 28% and symptomatic response in 43% patients. In comparison to published PRRT monotherapy outcomes in PGL, we did not observe any great advantage of concomitant therapy; however, it could be due to under-powered study. We recommend a large randomized trial to prove or disprove the utility of capecitabine as a radiosensitizer for PRRT in PGL patients.
Source: EJNMMI Research - Category: Radiology Source Type: research